Ignite Creation Date:
2025-12-24 @ 11:17 PM
Ignite Modification Date:
2026-01-04 @ 4:36 PM
Study NCT ID:
NCT02945956
Status:
UNKNOWN
Last Update Posted:
2020-02-13
First Post:
2016-10-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006975', 'term': 'Hypertension, Portal'}, {'id': 'D006509', 'term': 'Hepatitis B'}], 'ancestors': [{'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D018347', 'term': 'Hepadnaviridae Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D006525', 'term': 'Hepatitis, Viral, Human'}, {'id': 'D006505', 'term': 'Hepatitis'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C413685', 'term': 'entecavir'}, {'id': 'C532829', 'term': 'fuzheng huayu'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 192}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2018-04-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-02', 'completionDateStruct': {'date': '2021-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2020-02-11', 'studyFirstSubmitDate': '2016-10-23', 'studyFirstSubmitQcDate': '2016-10-24', 'lastUpdatePostDateStruct': {'date': '2020-02-13', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-10-26', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2020-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of clinical events: Variceal hemorrhage, Ascites, Encephalopathy, etc', 'timeFrame': '96 weeks'}, {'measure': 'Grading varices', 'timeFrame': '96 weeks'}, {'measure': 'Incidence of Liver cancer', 'timeFrame': '96 weeks'}, {'measure': 'Noninvasive portal hypertension index', 'timeFrame': '96 weeks'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Portal Hypertension', 'Fuzheng Huayu', 'Hepatitis B'], 'conditions': ['Portal Hypertension']}, 'descriptionModule': {'briefSummary': 'Portal hypertension is a common pathology in chronic liver disease, particularly in liver cirrhosis. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China. The basic reason for portal hypertension in HBV is the largely deposition of hepatic extracellular matrixes which causes high pressure in liver vessels. One of the most common symptoms of cirrhotic portal hypertension is gastroesophageal varices.The effective inhibition of HBV can partially stop or reverse liver fibrosis in patients with chronic Hepatitis and liver cirrhosis due to HBV and the anti-fibrotic strategy focusing on the regulation of hepatic extracellular matrix may have a great benefit. Therefore, antivirals therapy is also a basic treatment for low-grade cirrhotic portal hypertension. Fuzheng Huayu has been found to enhance the degradation of collagens in fibrotic liver and have a good action against liver fibrosis in patients with chronic hepatitis B. However, there are no high quality clinical evidences which can demonstrate if the combination of anti-viral and anti-fibrotic therapy can relieve the pressure of liver vessels and decline incidence rate and bleeding rate of gastroesophageal varices.', 'detailedDescription': 'The primary objective of this study is to establish the safety and efficacy of the combination of Entecavir and Fuzheng Huayu for reverse rate of gastroesophageal varices in patients with low-grade cirrhotic portal hypertension due to hepatitis B virus.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* More than 6 months history of serum positive HBsAg\n* Abdominal ultrasonogram or CT scan or liver-biopsy specimen indicates liver cirrhosis\n* Age 18-65\n* Child-Pugh\\<7 (Stage A)\n* Without portal hypertension（Endoscopy indicates no signs of gastroesophageal varices.）\n* Low-grade of portal hypertension（Endoscopy indicates signs of gastroesophageal varices that is line shape without red wales or spots and less than 0.3cm of diameter.）\n* The patient or the patient's guardian agrees to participate the random controlled trial and sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* Primary Lamivudine, Adefovir dipivoxil and Entecavir resistance\n* Decompensated cirrhosis、The Child-Pugh score≥7\n* Moderate grade of portal hypertension（Endoscopy indicates signs of gastroesophageal varices that is line shape with red wales or spots and less than 0.3cm of diameter,or snake large shape without red wales or spots and less than 1.0cm of diameter.）\n* Severe grade of portal hypertension（Endoscopy indicates signs of gastroesophageal varices that is catenulate/nodular shape with or without red wales or spots and more than 1.0cm of diameter.）\n* Decompensated liver cirrhosis Liver cancer\n* Liver histology conform to other chronic liver disease cause (exclude fatty liver)\n* Non-HBV avihepadnavirus infected acute and chronic hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, inherited metabolic liver disease, drug or toxic hepatitis, Alcoholic liver disease.\n* Have psychiatric history or uncontrollable epilepsy patient.\n* Uncontrollable diabetic patient\n* History of Hemoglobin disease (such as Alpha globin generation barrier anemia, Sickle cell deficiency, Spherocytosis) or Hemolytic anemia patients caused by other reasons like autoimmunity.\n* Severe background disease like chronic respiratory failure, circulatory failure, kidney failure etc.\n* In situ organ transplantation (such as liver, kidney, lung and heart) or bone marrow transplantation and stem cell transplantation.\n* Immunocompromised patients: such as HIV infection or take immunosuppressor or glucocorticoid (such as cyclosporin, azathioprine, adrenocortical hormone) within 3 months or chemotherapy drugs (such as cyclophosphamide, ammonia and cancer chemotherapy) and radioactive therapy.\n* Gestation or lactation period women and women who plan to get pregnant during the study period.\n* Patient who are allergy to the experimental drug.\n* Using history of anti-viral or anti-fibrosis drug within 6 months.\n* Patients who are participating other trials.\n* Other situation where PI thinks the patient should be excluded."}, 'identificationModule': {'nctId': 'NCT02945956', 'briefTitle': 'Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir', 'organization': {'class': 'OTHER', 'fullName': 'ShuGuang Hospital'}, 'officialTitle': 'A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus', 'orgStudyIdInfo': {'id': 'SGHLC20161023003'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Entecavir', 'description': 'Tablet with Entrcavir', 'interventionNames': ['Drug: Entecavir']}, {'type': 'EXPERIMENTAL', 'label': 'Entecavir + Fuzheng Huayu', 'description': 'Tablet Tablet with Entrcavir+ Tablet with Fuzheng Huayu', 'interventionNames': ['Drug: Entecavir + Fuzheng Huayu']}], 'interventions': [{'name': 'Entecavir', 'type': 'DRUG', 'description': 'The subjects will be taking 1 Entecavir tablet per day for 96 weeks.', 'armGroupLabels': ['Entecavir']}, {'name': 'Entecavir + Fuzheng Huayu', 'type': 'DRUG', 'description': 'The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.', 'armGroupLabels': ['Entecavir + Fuzheng Huayu']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Shanghai', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'hui Wang', 'role': 'CONTACT'}], 'facility': 'Ruijin Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Shanghai', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Wei Jiang', 'role': 'CONTACT'}], 'facility': 'Shanghai Zhongshan Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Shanghai', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Jing Lv', 'role': 'CONTACT', 'phone': '021-20256409'}], 'facility': 'Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}], 'centralContacts': [{'name': 'JING LV, MD', 'role': 'CONTACT', 'email': 'liver125@126.com', 'phone': '+86-21-20256521'}], 'overallOfficials': [{'name': 'CHENGHAI LIU, PHD,MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'ShuGuang Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'ShuGuang Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'Ruijin Hospital', 'class': 'OTHER'}, {'name': 'Shanghai Zhongshan Hospital', 'class': 'OTHER'}, {'name': 'Longhua Hospital', 'class': 'OTHER'}, {'name': 'Shanghai Public Health Clinical Center', 'class': 'OTHER_GOV'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Liu Chenghai', 'investigatorAffiliation': 'ShuGuang Hospital'}}}}